MaxCyte announced the launch of ExPERT DTx

MaxCyte (MXCT) announced the launch of ExPERT DTx, a new high throughput transfection platform for research and drug discovery applications. “We’re extremely excited about the launch of the ExPERT DTx, which builds on the company’s established portfolio of best-in-class electroporation technologies,” said Maher Masoud, Chief Executive Officer of MaxCyte. “This cutting-edge platform provides researchers with deep insights into their experiments, helping them investigate the underlying biology of a cellular system before scaling up operations with confidence. We’ve developed this product around our customers’ needs, giving them the flexibility needed for research while delivering reproducible results with high cell viability at an affordable price.”